Roles of the urologist and nurse from the perspective of patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue therapy

被引:6
|
作者
Lebret, Thierry [1 ]
Bouregba, Alain [1 ]
机构
[1] Hop Foch, Dept Urol, F-92151 Suresnes, France
关键词
prostate cancer; hormonal therapy; LHRH agonist; professional-patient relations; multidisciplinary care; nurse-led services;
D O I
10.1111/j.1464-410X.2008.07785.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To establish the roles of the urologist, general practitioner (GP) and nurse from the perspective of the patient with prostate cancer receiving hormone therapy, and to assess patient satisfaction, in particular with management and information needs. PATIENTS AND METHODS Patients with prostate cancer receiving luteinizing hormone-releasing hormone analogue (LHRH-a) therapy were recruited by a representative sample of 58 French urologists (March to April 2007) and invited to complete a 42-item questionnaire. RESULTS In all, 350 representative patients participated in the study; > 90% were totally or quite satisfied with the information given by their urologist at diagnosis and the start of treatment. Their main contact during treatment was with the nurse who gave the injection (84% of patients). The nurse's main role was to provide clarity (60% of patients), guidance (35%) and support to the family (28%). Fewer patients discussed disease stage and progression with their nurse (29%) than with a doctor (urologist, 63%; or GP, 61%). Fewer also discussed treatment (24% vs 32%) but as many patients discussed the impact of their disease and treatment with their nurse as with their doctor (e.g. 33% discussed general health and fatigue with the nurse, vs 26% with the urologist). The need for contact with a health professional was greater during the early stages of treatment. Patients treated for < 12 months with 3-monthly injections were less likely to be in favour of spacing injections than patients treated for >= 3 years. CONCLUSION The patient consults the urologist for reliable information on disease and treatment, and to the GP for further support, if needed, but the nurse has the pivotal role. A 3-monthly injection schedule enables regular face-to-face contact between the nurse and the patient and their family, and contributes towards the patient's coping strategies and quality of life.
引用
收藏
页码:1419 / 1424
页数:6
相关论文
共 50 条
  • [1] Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer
    Shen, Yuan-Chi
    Kang, Chih-Hsiung
    Chiang, Po-Hui
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2016, 32 (11): : 567 - 571
  • [2] Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer
    Hatano, T
    Oishi, Y
    Furuta, A
    Iwamuro, S
    Tashiro, K
    BJU INTERNATIONAL, 2000, 86 (04) : 449 - 452
  • [3] Luteinizing hormone-releasing hormone antagonists in prostate cancer
    Stricker, HJ
    UROLOGY, 2001, 58 (2A) : 24 - 27
  • [4] Agonists of luteinizing hormone-releasing hormone in prostate cancer
    Rick, Ferenc G.
    Block, Norman L.
    Schally, Andrew V.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (16) : 2237 - 2247
  • [5] Luteinizing hormone-releasing hormone analogue-induced cataract in a patient with prostate cancer
    Al-Enezi, Ahmad
    Kehinde, Elijah O.
    Behbehani, Abdulla M.
    Sheikh, Zafar A.
    MEDICAL PRINCIPLES AND PRACTICE, 2007, 16 (02) : 161 - 163
  • [6] Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients
    Kaczmarek, Piotr
    Pokoca, Lech
    Niemirowicz, Jerzy
    Majewska, Ewa
    Baj, Zbigniew
    PHARMACOLOGICAL REPORTS, 2008, 60 (03) : 399 - 403
  • [7] Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer
    Wilke, Derek
    Patil, Nikhilesh
    Hollenhorst, Helmut
    Bowes, David
    Rutledge, Robert
    Ago, Casely
    PHARMACOTHERAPY, 2018, 38 (03): : 327 - 333
  • [8] Erratum to: Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients
    Piotr Kaczmarek
    Lech Pokoca
    Jerzy Niemirowicz
    Ewa Majewska
    Zbigniew Baj
    Pharmacological Reports, 2009, 61 (1) : 193 - 193
  • [9] Controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer
    Zerbib, M
    Payan, C
    UROLOGY, 1996, 48 (04) : 661 - 662
  • [10] Uncommon course of carcinoma of the prostate after radical prostatectomy and luteinizing hormone-releasing hormone analogue therapy
    Pauer, W
    Eckerstorfer, GM
    JOURNAL OF UROLOGY, 1998, 160 (04): : 1432 - 1433